Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

BACKGROUND: Treatment outcomes remain poor in recurrent platinum-resistant ovarian cancer. Enadenotucirev, a tumor-selective and blood stable adenoviral vector, has demonstrated a manageable safety profile in phase 1 studies in epithelial solid tumors. METHODS: We conducted a multicenter, open-label...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno, Victor, Barretina-Ginesta, Maria-Pilar, García-Donas, Jesús, Jayson, Gordon C, Roxburgh, Patricia, Vázquez, Raúl Márquez, Michael, Agnieszka, Antón-Torres, Antonio, Brown, Richard, Krige, David, Champion, Brian, McNeish, Iain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666888/
https://www.ncbi.nlm.nih.gov/pubmed/34893524
http://dx.doi.org/10.1136/jitc-2021-003645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666888/
https://www.ncbi.nlm.nih.gov/pubmed/34893524
http://dx.doi.org/10.1136/jitc-2021-003645

Ejemplares similares